Ioannis Gounaris
Feltham, ENG, United Kingdom
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 31 publications
Pathway for the Development of ATR Inhibitors in Pediatric Malignancies: An ACCELERATE Multistakeholder Analysis.
Journal: JCO precision oncology
Published: January 15, 2026
An Integrated Nonclinical and Clinical Risk Assessment of the Effects of Investigational ATRi Tuvusertib on QTc Interval in Patients With Solid Tumors.
Journal: Clinical and translational science
Published: September 04, 2025
Integrated Population Pharmacokinetic, Pharmacodynamic, and Safety Analyses to Inform Dosage Selection in the Clinical Development of the ATR Inhibitor Tuvusertib.
Journal: Clinical pharmacology and therapeutics
Published: December 18, 2024
First-in-Human Study of the Ataxia Telangiectasia and Rad3-Related (ATR) Inhibitor Tuvusertib (M1774) as Monotherapy in Patients with Solid Tumors.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: August 10, 2023
A phase I study of ATR inhibitor gartisertib (M4344) as a single agent and in combination with carboplatin in patients with advanced solid tumours.
Journal: British journal of cancer
Published: April 07, 2023
Paediatric Strategy Forum for medicinal product development of DNA damage response pathway inhibitors in children and adolescents with cancer: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration.
Journal: European journal of cancer (Oxford, England : 1990)
Published: March 06, 2023
Relationship among DDR gene mutations, TMB and PD-L1 in solid tumour genomes identified using clinically actionable biomarker assays.
Journal: NPJ precision oncology
Published: February 25, 2023
Practical implementation of the partial ordering continual reassessment method in a Phase I combination-schedule dose-finding trial.
Journal: Statistics in medicine
Published: December 03, 2021
Ribociclib, a CDK 4/6 inhibitor, plus endocrine therapy in Asian women with advanced breast cancer.
Journal: Cancer science
Published: February 27, 2020
Overall Survival with Ribociclib plus Endocrine Therapy in Breast Cancer.
Journal: The New England journal of medicine
Published: June 06, 2019
6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial.
Journal: Lancet (London, England)
Published: December 13, 2018
Last Updated: 09/26/2026